Patient Centricity

Science Collective

At Piramal Pharma Solutions, our commitment to excellence is embodied by our esteemed “Science Collective”-a team of profoundly experienced and highly educated professionals dedicated to resolving the complex technical challenges our clients face. This elite group’s extensive background in the pharmaceutical industry equips them with a nuanced understanding of the intricacies and hurdles inherent in pharmaceutical development.

Jean-Francois Carniaux, PhD

Jean-Francois Carniaux, PhD

VP and Global API Technical Lead

As Vice President and Global API Technical Lead at Piramal Pharma Solutions, JF provides comprehensive scientific oversight and project orientation to our small molecule API business. JF is a vital cog in our API machine, providing guidance on all API/HPAPI projects developed and manufactured at our drug substance sites in the US, Canada, UK, and India. His input begins with the project evaluation, continues through development support, and culminates in the delivery of the API for our customers and their patients.

Over the past 25+ years, JF has built a highly regarded legacy of expertise in API development and manufacturing that spans experience on both the contract services and innovator company sides of drug development and manufacturing.

His Career Highlights Include:

  • Successfully driven more than 200 molecules from laboratory to plant manufacturing through various stages of clinical development
  • Completed multiple validation and commercial supply projects as a CDMO and as a CMC team member in pharmaceutical companies
  • Provided GMP compliance and audit support for pharmaceutical development within the CMC function
  • Preparation of scientific justification to support regulatory agency meetings
  • Implemented solid state activities supporting crystallization and polymorph control within a process and development unit
  • Developed, coached, and trained teams of chemists to add value and identify solutions to complex challenges
  • Established streamlined approaches for conducting process R&, encompassing both the typical R& elements and special considerations to ensure successful manufacturing scale-up

JF’s biography:

  • MSc Degree in Chemical Engineering and Ph.D. in Organic Chemistry from the Faculty of Pharmacy, Paris
  • 25+ Years of experience in CDMO (Evotec, Aptuit) and Biotech/Pharmaceutical organizations (Summit Pharmaceutical, Circassia, Shire)
  • Holder or co-author of more than 15 industry patents or technical papers
  • In addition to being part of the Science Collective, JF is also a member of the Piramal Pharma Solutions Client Advisory Board

JF is available to share his expertise with our clients, in person or via a virtual session. To arrange a meeting send an email to jean-francois.carniaux@piramal.com.

Thomas B. Gold, PhD

Thomas B. Gold, PhD

Global Formulations R&D Head

Piramal Pharma Solutions is proud to include Brad Gold as a member of our Science Collective. Brad has an outstanding legacy of scientific excellence built over 30+ years in the industry. As our Global Formulations R&D Head, Brad provides complete scientific oversight for Piramal's drug product formulations business. He is an integral part of the operations at our formulation sites in the US, UK and India, and a valuable resource to all of our drug product customers.

Over the course of his career, Brad has established a proven track record of solving formulation and process challenges in pharmaceutical development, directing operations, containment design and implementation, continuous improvement, and people engagement.

His Career Highlights Include:

  • Oversight of precommercial activities, including clinical trial manufacturing, at Catalent Pharma Solutions
  • Responsibility for all formulation and process development at Metrics Contract Services
  • Implementation of operational excellence modules together with reporting and tracking systems, application of lean principles, and quality by design
  • GMP compliance and audit support for the complete pharmaceutical development function
  • Evaluation and implementation of new technology platforms, including highly potent manufacturing capabilities

Brad’s biography:

  • MS in Chemistry and a PhD in Pharmaceutics & Medicinal Chemistry from the University of Kentucky
  • Holder of 5 industry patents related to sustained release, zero-order release, and near zero-order release formulations
  • Author or co-author of more than 20 published technical papers
  • In addition to being part of the Science Collective, Brad is also a member of the Piramal Pharma Solutions Client Advisory Board

Brad’s expertise is an asset that is available to all our clients, in person or via a virtual session. To arrange a meeting send an email to brad.gold@piramal.com.

Matteo Villain, PhD

Matteo Villain, PhD

VP and Global Peptide Lead

As a key member of the Piramal Pharma Solutions Science Collective - our "brain trust" of leading scientific subject matter experts &ndash Matteo provides comprehensive technical oversight for our Peptide API business. His role is ensuring seamless management of peptide APIs from initial project evaluation to customer interaction. His responsibilities extend to guiding the development process, facilitating tech transfers into GMP manufacturing, troubleshooting operational issues, shaping development strategy, and defining the CMC path. In essence, Matteo shoulders the responsibility of supporting Piramal's customers throughout the entire Peptide API life cycle.

With an impressive 20-year track record in Contract Development and Manufacturing Organization (CDMO) roles, Matteo brings a wealth of expertise in peptide API development, GMP commercial manufacturing, CMC development, and API life cycle management to the Piramal organization.

His career highlights include:

  • Successful navigation of over 70 projects through various stages of clinical development, culminating in the commercial launch of five products
  • Development of peptide drug products across multiple therapeutic areas
  • Successful creation of multiple PEG-conjugated commercial peptide APIs
  • Handling of products with complex, multi-cyclic structures
  • Demonstrated excellence in delivering generic peptide drug products, overcoming technological challenges and restrictions

Matteo’s biography:

  • Doctor of Medicinal Chemistry and Pharmaceutical Science - University of Milano, Faculty of Pharmacy
  • Holder of 5 industry patents
  • Recent publications:
    • Gober IN, Sharan R, Villain M. Improving the stability of thiol&ndashmaleimide bioconjugates via the formation of a thiazine structure. J. Pept. Sci. 2023 Jul29(7): e3495.
    • Gober IN, Riemen JA, Villain M. Sequence sensitivity and pH dependence of maleimide conjugated N-terminal cysteine peptides to thiazine rearrangement. J. Pept. Sci. 2021 Jul27(7): e3323.
  • 20+ years of experience in the CDMO market
  • Fluent in Italian, English and French

Matteo is available to consult with you in person or via a virtual session. To arrange a meeting send an email to matteo.villain@piramal.com.

Conor Barry, PhD

Conor Barry, PhD

Associate VP, Global Biologics Technical Lead

Conor Barry, Ph.D., is the Global Biologics Technical Lead at Piramal Pharma Solutions. He leads our bioconjugate programs, leveraging his deep scientific and technical expertise to oversee critical research and drive successful outcomes.

With over 15 years of specialized experience in the field, Conor has played a pivotal role in the development and CMC filing of numerous bioconjugates. His exceptional technical acumen and strong leadership capabilities enable him to steer our bioconjugate initiatives through complex challenges, ultimately helping deliver transformative health solutions for patients.

His Career Highlights Include:

  • Overseeing a pilot site with a 55+ member team responsible for advancing over 40 bioconjugates into clinical trials and two into commercial production
  • Improving R&D capabilities by developing a network of CRO and CMO contractors and a focused in-house R&D facility
  • Spearheading the development of an IP-protected novel and scalable manufacturing process for a multi-billion-selling generic peptide drug
  • Leading a cross-site, cross-disciplinary team to deliver a company-wide database of pre-clinical project data that was later used to draw insights for the design of better-tolerated targeted therapeutics

Conor’s biography:

  • BSc (Hons) in Chemistry from the University College Cork and Ph.D. in Organic Chemistry from the University of Bristol
  • Postgraduate Diploma in Strategy & Innovation from the University of Oxford (Saïd Business School)
  • Post-doctoral Research at the University of Oxford, the University of Nottingham, and Johns Hopkins University
  • Member of the Industrial Advisory Board for the University of Edinburgh
  • Co-author of over 20 peer-reviewed scientific publications
  • 15+ years of experience in the bioconjugate field

Conor is passionate about enhancing patients’ lives. As an expert in bioconjugates, he offers his full support to customers working to develop groundbreaking treatments in the field. He is happy to consult with you in person or via a virtual session. To arrange a meeting, email conor@piramal.com.

Sundar Neelkanth, PhD

Sundar Neelkanth, PhD

Director of Development, Fill-Finish

Dr. Sundar Neelakantan is a key member of our esteemed Science Collective. Known to most as Sunny, Dr. Neelakantan is the Director of Development at Piramal Pharma Solutions&rsquo Lexington, Kentucky facility. In this pivotal role, he oversees all formulation and analytical development activities, providing technical direction, training, and mentorship to the site's teams.

Sunny plays a crucial role in business development, engaging with clients to support Requests for Proposals (RFPs), reviewing proposals, and guiding the successful launch of new projects. He expertly manages and monitors project progress to ensure milestones are achieved on time while maintaining budgetary constraints and optimizing revenue. Sunny facilitates the Lexington site's critical role in our integrated ADCelerate&trade program as the sterile fill/finish facility, actively contributing to its work on ADCelerate&trade initiatives.

With over 23 years of experience in the pharmaceutical industry, Sunny's expertise spans a wide range of drug products, including small molecules, peptides, and biologics. He has extensive experience in clinical and commercial manufacturing of high-potent drug products using isolator-based technology. His specialization includes lyophilization cycle development (aqueous and co-solvent-based), liposomal formulation, lipid-based nano-emulsions and nanoparticles, and micro suspensions. He is an expert in product development, applying Quality by Design (QbD) principles, CMC regulatory strategy, FMEA, and technical risk assessment.

Some of Sunny’s career highlights include:

  • Key contributor and member of the product development team responsible for the development and successful commercialization of three (3) new drug products and several ANDAs.
  • Led the development of parenteral drug products, including lyophilization cycle development and tech transfer
  • Generated documentation for regulatory submissions, including ANDA filings, while supporting technology transfer processes
  • Developed lyophilization cycles for both small molecules and biologics
  • Conducted comprehensive compatibility studies for excipients and manufacturing components to optimize the stability and performance of formulations

Sunny’s biography:

  • B.Sc in Chemistry (First class) from the University of Madras, Chennai, India
  • M.S. in Chemistry (First class) from the University of Madras, Chennai, India
  • Ph.D. Organic /Medicinal Chemistry from the Indian Institute of Technology, Mumbai, India
  • Postdoctoral training in Drug Design and Discovery (DDD) and Pharmaceutics from the College of Pharmacy, University of Kentucky
  • Three-day hands-on training in lyophilization cycle development at SP Scientific in Stone Ridge, NY
  • High Potent API handling Boot Camp I and II training at Safe Bridge Inc.
  • Over 25 academic publications
  • Four patents
  • 30+ conference presentations

Each member of the Science Collective has advanced degrees in relevant fields, ensuring a foundation of knowledge that is both deep and broad. Their educational achievements are complemented by substantial hands-on technical experience, having honed their expertise across leading CDMOs. This combination of theoretical knowledge and practical experience makes our team uniquely capable of navigating the multifaceted challenges presented in drug development.

They approach each challenge with a solution-oriented mindset, ready to tackle even the most daunting of problems. Whether it involves small molecules, peptides, Antibody Drug Conjugates (ADCs), or biologics, our team ensures that no issue goes unaddressed, accelerating project timelines and enhancing the overall development process. Furthermore, their multidisciplinary approach spans a wide array of domains, from synthetic chemistry to process development to commercial manufacturing, enabling them to provide comprehensive solutions across the entire spectrum of drug development. This versatility not only enhances our service offering but also reinforces our commitment to meeting patient needs with precision and efficiency.

By entrusting your project to the Science Collective at Piramal Pharma Solutions, you gain more than just expert service you acquire a proactive partnership dedicated to your project's success, from conception through to commercialization.

Thank You for your Interest. Please enter your details.
loader